Home » Newsletters » BioWorld Science

BioWorld Science

July 6, 2011

View Archived Issues

Preclinical and phase I data show LY-2409021 lowers glucose

Preclinical and clinical phase I and II data reported on antidiabetes agent MK-0893

Scripps Research Institute describes first potent lysophospholipid S1P4 receptor antagonists

GSK discloses new lysophospholipid S1P1 receptor agonists

Chimerix and BARDA reach agreement regarding sole-source contract for smallpox antiviral

Almirall launches Sativex in Germany for treatment of spasticity due to MS

Resverlogix's RVX-297 shows promise in model of multiple sclerosis

Boehringer Ingelheim claims new chemokine CCR2 receptor antagonists

New tachykinin NK3 receptor antagonists designed by Roche

Novel serine/threonine-protein kinase Chk1 inhibitors patented

Lundbeck presents new phosphodiesterase 10A inhibitors

Merck KGaA synthesizes new sphingosine kinase 1 inhibitors

Amgen and UCB join with NASA to test sclerostin-targeted antibody onboard space shuttle Atlantis

GSK receives approvals in Japan for Rotarix and Lamictal

Scancell's SCIB-2 cancer vaccine shows encouraging preclinical results

Sorrento Therapeutics is granted second phase I NIAID grant for MRSA program

Urigen and FDA set next steps for URG-101 study in interstitial cystitis

Chugai receives Japanese approval for additional indication of Pegasys/Copegus combination

Once-monthly minodronic acid formulation approved in Japan

BioLineRx enrolls first subject in phase I BL-1021 trial for neuropathic pain

FDA grants orphan drug status to INNO-206 in soft tissue sarcomas

FDA approves Archimedes Pharma's Lazanda for breakthrough cancer pain

Rib-X Pharmaceuticals and Sanofi enter collaboration to develop new classes of antibiotics

Nuvo Research receives FDA clearance to begin clinical testing of lidocaine spray

RESprotect reacquires North American rights to RP-101

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.